Abstract:Objective: To investigate the potential of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in mitigating the adverse prognosis associated with central nervous system leukemia (CNSL) and to assess the significance of prophylactic intrathecal injection. Methods: A retrospective cohort analysis was conducted involving 30 patients with acute leukemia who had a history of CNSL who underwent allo-HSCT at Peking University People's Hospital between September 2012 and March 2018 (referred to as the CNSL-positive group). In addition, 90 patients with acute leukemia were selected from the same period who underwent allo-HSCT without a history of CNSL (referred to as the CNSL-negative group) and a rigorous 1∶3 matching was performed based on disease type, disease status, and transplantation type to form the control group. The prognosis between the two groups was compared using Kaplan-Meier analysis and the high-risk factors for CNSL relapse post-transplant were identified through Cox proportional-hazards model. Results: The median age of patients in the CNSL-negative group was significantly higher than that of patients in the CNSL-positive group (32 years vs. 24 years, P=0.014). No significant differences were observed in baseline data, including sex, disease type, disease status at transplantation, donor-recipient relationship, and human leukocyte antigen consistency between the two groups. The median follow-up time was 568 days (range: 21-1 852 days). The 4-year cumulative incidence of relapse (71.4%±20.9% vs. 29.3%±11.5%, P=0.005) and the cumulative incidence of CNSL post-transplant (33.6%±9.2% vs. 1.2%±1.2%, P<0.001) were significantly higher in the CNSL-positive group than in the CNSL-negative group. Furthermore, the 4-year leukemia-free survival rate in the CNSL-positive group was significantly lower than that in the CNSL-negative group (23.1%±17.0% vs. 71.5%±11.6%, P<0.001). However, no significant differences were observed in the 4-year cumulative transplant-related mortality and overall survival rates between the two groups (both P>0.05). Multivariate analysis revealed that a history of CNSL before transplantation (HR=25.050, 95%CI 3.072-204.300, P=0.003) was identified as high-risk factors for CNSL relapse post-transplant. Conversely, haploidentical transplantation was associated with a reduced risk of CNSL relapse post-transplant (HR=0.260, 95%CI 0.073-0.900, P=0.034). Within the CNSL-positive group, seven patients received prophylactic intrathecal therapy after transplantation, and their CNSL relapse rate was significantly lower than that of the 23 patients who did not receive intrathecal therapy after transplantation (0/7 vs. 9/23, P=0.048). Conclusions: Patients with a history of CNSL have a higher risk of relapse and experience poorer leukemia-free survival following transplantation. The use of prophylactic intrathecal injection shows promise in mitigating CNSL relapse rates, although further validation through prospective studies is necessary to substantiate these observations.

Predictive Role of Cerebrospinal Fluid Hydrogen Sulfide in Central Nervous System Leukemia

Cerebrospinal Fluid IL-6 and IL-10 As Promising Diagnostic and Therapeutic Prognostic Biomarkers for Secondary Central Nervous System Lymphoma

Immune Regulation of Hydrogen Sulfide in Children with Acute Lymphoblastic Leukemia.

Diagnosis and treatment of acute leukemia with central nervous system infiltration

Expression of S100B Protein Levels in Serum and Cerebrospinal Fluid with Different Forms of Neuropsychiatric Systemic Lupus Erythematosus.

Surrogate biomarkers identification for neuropsychiatric lupus by proteomic fingerprint technology

Metabolomic profiling of cerebrospinal fluid reveals an early diagnostic model for central nervous system involvement in acute lymphoblastic leukaemia

Changes of Serum Hydrogen Sulfide Levels in Acute Leukemia Children with Daunorubicin -Induced Myocardial Damage

Prognostic significance of CNSL at diagnosis of childhood B-cell acute lymphoblastic leukemia: A report from the South China Children’s Leukemia Group

Biomarkers in Pediatric Hemophagocytic Lymphohistiocytosis With Central Nervous System Involvement: A Cohort Study

Diagnostic Value and Prognosis Significance of Cerebrospinal Fluid Examination by Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia

Diagnostic Value of sLR11 and sIL-2R in the Cerebrospinal Fluid for Malignant Central Nervous System Lymphoma

Cerebrospinal fluid interleukin-6 is a potential diagnostic biomarker for central nervous system involvement in adult acute myeloid leukemia

Diagnostic significance of cerebrospinal fluid flow cytometry in Chinese children with B lineage acute lymphoblastic leukemia

[Prognostic Analysis of Patients with Acute Leukemia and Central Nervous System Involvement Undergoing Allogeneic Hematopoietic Stem Cell Transplantation].

Cerebrospinal Fluid Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study in China

The plasma‐soluble CSF1R level is a promising prognostic indicator for pediatric Langerhans cell histiocytosis

[Clinical Characteristics and Prognosis of 21 Cases of Acute Lymphoblastic Leukemia with Central Nervous System Leukemia]

Radiographic Manifestations and Clinical Relevance to Central Nervous System Complications of Leukemia in Chilq Dren

Clinical study of central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation

Changes in Serum Levels of Endogenous Sulfur Dioxide in Childhood Acute Lymphoblastic Leukemia with Neutropenia and Gram-Negative Bacteria Infection and Its Significance of Pathophysiological Role